Mylab Discovery Solutions, a pioneer in healthcare diagnostics, is set to revolutionize new-born screening (NBS) with the introduction of its groundbreaking Point-of-Care Device, MyNeoShield. This innovative device promises to make new-born screening faster, more accessible, and cost-effective, potentially saving lives and preventing lifelong illnesses. MyNeoShield is designed to support all seven essential tests conducted globally for new-born screening.
Traditionally, new-born screening has been a laborious process, involving sample collection, transportation to centralized testing centers, and a lengthy wait of up to a day or more for results. This complex process presented significant challenges, particularly in remote areas where timely intervention is crucial within a 48-hour window. Additionally, the high costs of specialized equipment posed a hurdle for smaller healthcare facilities like nursing homes, limiting their ability to provide these critical tests.
Mylab’s innovative device addresses these challenges by bringing new-born screening directly to healthcare providers at the point of care, and here’s why it’s a game-changer:
- Swift Results (6x Faster): Mylab’s device delivers new-born screening results in just 4 hours, a remarkable improvement compared to traditional methods that take up to 24 hours post-sample receipt, and sometimes even longer. This rapid turnaround ensures that any potential health concerns are promptly identified and addressed.
- Enhanced Accessibility: Smaller healthcare facilities, including clinics and nursing homes, can now offer new-born screening without the need for costly equipment or extensive resources. This means that even in rural or remote areas, infants can receive the necessary care right from birth.
- Life-Saving Impact: Early detection of conditions through new-born screening is pivotal in preventing mental retardation, mortality, and lifelong illnesses that can be easily averted with timely intervention. Mylab’s device empowers healthcare providers to make a significant impact on the well-being of newborns.
Hasmukh Rawal, Co-founder & Managing Director of Mylab, expressed his enthusiasm for this development, stating, “At Mylab, we are deeply committed to advancing healthcare through innovation and accessibility. Our Point-of-Care Device for New-born Screening is a testament to that commitment. By making screening faster and more accessible, we aim to save lives and ensure that every child has the opportunity for a healthy and promising future.”
This Point-of-Care Device for Newborn Screening is expected to be commercially available from November. Mylab plans to introduce the device to global markets through its partnerships. New-born screening (NBS) is a vital public health program that involves testing newborn infants for specific genetic, metabolic, and congenital disorders shortly after birth. Left undiagnosed and untreated, these conditions can lead to severe developmental issues and lifelong health challenges.
List of Tests Covered:
- G-6-Phosphate Dehydrogenase Deficiency (G-6-PDD)
- Galactosemia
- Phenylketonuria (PKU)
- Biotinidase Deficiency
- 17-Hydroxyprogesterone (17-OHP)
- Immunoreactive Trypsinogen (IRT)
- Thyroid-Stimulating Hormone (TSH)
Mylab Discovery Solutions, an Indian biotech firm, specializes in the development and commercialization of Molecular, Serological, Immunology, Imaging, Biochemistry, and Hematology testing solutions. Their focus includes building Automated POC (Point-of-Care) systems for applications in clinical diagnostics, drug discovery, biomedical research, Agri genomics, animal health, and food safety.
